Congenital Hyperinsulinism (CHI)

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Congenital Hyperinsulinism (CHI) trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 2

NCT04732416

HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)

This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15136 when used as add-on therapy in subjects with CHI wit…

United States, Germany +2 more16 participantsStarted 2022-05-05

Treatment: HM15136

All recent trials (6 shown)

AVAILABLENot Applicable

NCT01916148

18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia

This purpose of this study is to determine the ability of an 18F-fluoro-L-dihydroxyphenylalanine (18F-DOPA) PET (Positron Emission Tomography) scan to detect a…

Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism

Children with congenital hyperinsulinism (CHI) have low blood sugar, and some of these children may require surgery. In this study, researchers affiliated with…

United States106 participantsStarted 2004-12

Treatment: F-DOPA, PET scan

Congenital Hyperinsulinism (CHI)

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)

All recent trials (6 shown)

18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia

Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)

All recent trials (6 shown)

18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia

Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism

Phase II Safety and Efficacy Study of 18FDOPA PET-CT in Children With Hyperinsulinemic Hypoglycemia

GLP-1 Receptor Expression in CHI

Long Term Glucose Metabolism in Conservatively Treated Patients With Congenital Hyperinsulinism